In a Phase II study, patients with OAG or OHT who had an unmedicated IOP between ≥22 mmHg to <36 mmHg were randomized to receive razuprotafib every day alongside latanoprost, a commonly used medication for glaucoma. For patients receiving a combination of twice-daily razuprotafib and ...